First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients

Five-year deal aims to support UK biomedical talent and drive collaboration across sectors

Positive topline results highlight potential new option for secondary stroke prevention

Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases

New patent strengthens IP position for treatment of influenza side effects

Protara’s phase 2 STARBORN-1 study reports high response rates and no serious adverse events

New authorisation marks major milestone in earlier treatment of skin cancer

Munich-based start-up backed by Frontline Ventures and Y Combinator eyes global expansion

Six new Grand Challenges aim to tackle drug resistance and accelerate antibiotic discovery